257 related articles for article (PubMed ID: 24761842)
1. Triple negative breast cancer.
Cetin I; Topcul M
Asian Pac J Cancer Prev; 2014; 15(6):2427-31. PubMed ID: 24761842
[TBL] [Abstract][Full Text] [Related]
2. Triple-negative breast cancer molecular subtyping and treatment progress.
Yin L; Duan JJ; Bian XW; Yu SC
Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
[TBL] [Abstract][Full Text] [Related]
3. New targets for triple-negative breast cancer.
Herold CI; Anders CK
Oncology (Williston Park); 2013 Sep; 27(9):846-54. PubMed ID: 24282978
[TBL] [Abstract][Full Text] [Related]
4. Potential role of targeted therapies in the treatment of triple-negative breast cancer.
Jia LY; Shanmugam MK; Sethi G; Bishayee A
Anticancer Drugs; 2016 Mar; 27(3):147-55. PubMed ID: 26682525
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancer: is there a treatment on the horizon?
Yao H; He G; Yan S; Chen C; Song L; Rosol TJ; Deng X
Oncotarget; 2017 Jan; 8(1):1913-1924. PubMed ID: 27765921
[TBL] [Abstract][Full Text] [Related]
6. Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.
Hamilton N; Marquez-Garban D; Mah VH; Elshimali Y; Elashoff D; Garon EB; Vadgama J; Pietras R
Crit Rev Oncog; 2015; 20(5-6):373-90. PubMed ID: 27279236
[TBL] [Abstract][Full Text] [Related]
7. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
8. Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
Damaskos C; Garmpi A; Nikolettos K; Vavourakis M; Diamantis E; Patsouras A; Farmaki P; Nonni A; Dimitroulis D; Mantas D; Antoniou EA; Nikolettos N; Kontzoglou K; Garmpis N
Anticancer Res; 2019 Oct; 39(10):5285-5296. PubMed ID: 31570423
[TBL] [Abstract][Full Text] [Related]
9. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
Williams CB; Soloff AC; Ethier SP; Yeh ES
Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
[TBL] [Abstract][Full Text] [Related]
11. Targeted approaches to triple-negative breast cancer: current practice and future directions.
Brunello A; Borgato L; Basso U; Lumachi F; Zagonel V
Curr Med Chem; 2013; 20(5):605-12. PubMed ID: 23278396
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
Nagini S
Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
[TBL] [Abstract][Full Text] [Related]
13. PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.
Zhao H; Li D; Zhang B; Qi Y; Diao Y; Zhen Y; Shu X
Molecules; 2017 Dec; 22(12):. PubMed ID: 29261144
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.
Garmpis N; Damaskos C; Garmpi A; Kalampokas E; Kalampokas T; Spartalis E; Daskalopoulou A; Valsami S; Kontos M; Nonni A; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Cancer Genomics Proteomics; 2017; 14(5):299-313. PubMed ID: 28870998
[TBL] [Abstract][Full Text] [Related]
15. BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds.
Hongthong K; Ratanaphan A
Curr Cancer Drug Targets; 2016; 16(7):606-17. PubMed ID: 26845433
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathways: PI3K pathway targets in triple-negative breast cancers.
Gordon V; Banerji S
Clin Cancer Res; 2013 Jul; 19(14):3738-44. PubMed ID: 23748695
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.
Nath A; Mitra S; Mistry T; Pal R; Nasare VD
Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker.
O'Conor CJ; Chen T; González I; Cao D; Peng Y
Biomark Med; 2018 Jul; 12(7):813-820. PubMed ID: 29902924
[TBL] [Abstract][Full Text] [Related]
19. Recent Progress in Triple Negative Breast Cancer Research.
Mouh FZ; Mzibri ME; Slaoui M; Amrani M
Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
